Akaal Pharma has completed multiple Phase-1 (proof of concept) clinical trials of its topical drug candidate AKP-11 for the treatment of patients with atopic dermatitis, psoriasis and arthritis. In these clinical studies, AKP-11 was found to be safe, well tolerated and effective.
The current available topical treatments for dermatology (atopic dermatitis, psoriasis) suffer from various local and systemic adverse side effects including skin irritation, skin thinning and others. AKP-11 has shown safer profile as a topical therapy and demonstrated significant efficacy in reducing disease severity and disease area.Phase 2 clinical trials for the topical treatment of atopic dermatitis and psoriasis are underway.
The treatments available for pain alleviation have adverse side effects and an effective pain relieving therapy is needed for arthritis patients. AKP-11 has shown safer profile with fast onset in pain relief. One week of treatment with AKP-11 gave significant pain relief in arthritis patients. A Phase 2 clinical trial for the topical treatment of arthritis with moderate-to-severe pain will start in Q3’ 2017.
In addition, Phase-1 clinical trial is also planned for the use of our oral treatment for autoimmune and inflammatory diseases particularly multiple sclerosis and ulcerative colitis.